“The tech sector is once again outperforming the overall market in 2020 as investors continue to go all-in on growth,” observes the author of today’s article. However, the tech giants that have led the market’s rise may have limited upside left in the near term, and tech investors may be better off focusing on small-cap tech stocks. For seven high-quality…
Based on the premise that tech is poised to continue to drive the market for years to come, today’s article highlights three cheap (trading under $10 a share) stocks from the broader technology space to consider due to their growth prospects regardless of renewed market volatility. For more on these three tech stocks, CLICK HERE.
For “investors interested in stocks on the way down”, today’s article identifies two stocks that look bearish this week – and which investors may want to research further as potential candidates for shorting. For these two stocks – a maker of integrated circuits and a sports and entertainment giant – CLICK HERE.
While buying right now may be too risky for the average investor, the small-cap biotech highlighted in today’s article could be worth keeping an eye on, even as it (and many other promising biotech stocks) may have slipped under the radar as attention has shifted to potential COVID-19 plays (which this stock is not). Why? The company’s drug candidate for…
The biotech stock highlighted in today’s article is one of the many that has surged over the last few months due to its status as a potential COVID-19 play, with the company in question being the producer of a COVID-19 test. As with all the smaller biotechs that have been experiencing COVID-19-related surges lately, however, the question is whether that…
“Understandably, investors have taken a more cautious approach when navigating the confused financial environment, but focus is locking in on the biotech sector as it has been able to withstand the COVID-19-induced pressure on the market,” notes the author of today’s article. She proceeds to highlight three “Strong Buy”-rated biotech stocks trading for less than $5 a share that, with…
In the current market environment, the author of today’s article notes that “As a stock picker, it’s important to find areas where the risk and reward proposition is more positive,” and advises that “One of the areas where this is best exhibited is with emerging markets.” He proceeds to highlight three emerging market stocks trading at big discounts based on…
The “sleeper” biotech highlighted in today’s article, a company with a unique name and focused on therapies for very rare, pediatric cancers, has a promising pipeline – including two drugs that could be approved in the next year. This, combined with the fact that its stock price has steadily increased since its IPO (despite getting caught up in the coronavirus…
Biotech stocks have been experiencing a healthy bounce, with the largest ETF that tracks the group recently hitting an all-time high following the announcement from Moderna that it was seeing early positive results with its coronavirus vaccine candidate. Some traders are cautioning investors to “tread carefully” when it comes to buying in to biotech stocks at their current levels, however,…
It’s the most popular investing theme this year: COVID-19 vaccine producers. However, the recent reversal of fortunes for the stock of one biotech firm – whose stock had nearly tripled since the beginning of March when the firm announced it was working on a vaccine for the novel coronavirus – illustrates the risk involved with “chasing vaccine hype”. For more,…